Malnutrition and inappropriate prescribing of renally excreted drugs are common among older persons and are associated with severe consequences such as complicated courses of treatment, mortality, and reduced quality of life. The overall purpose of CanPan is to optimize treatment of older persons with malnutrition with a focus on appetite stimulation and optimized prescribing of renal risk drugs. The CanPan trial consists of two sub-studies. Substudy 1 will provide knowledge on appetite and appetite stimulation and together, sub study 1 and 2 will offer unique knowledge on how body composition, renal function and biomarkers of organ function influence pharmacokinetics for a highly lipophilic (Sativex®) and hydrophilic (Hexamycin®) drug in older medical patients with malnutrition.
The CanPan trial consists of sub study 1 and sub study 2. Subjects who meet all the inclusion criteria and none of the exclusion criteria are invited to participate in both sub studies. Sub study 1 consist of trial days 1 and 2 and sub study 2 consists of trial day 3. Sub study 1: Sub study 1 is a double-blinded, randomized, placebo-controlled, multidose, crossover trial that evaluates the appetite stimulating effect as well as the pharmacokinetics of Sativex®. The primary purpose of sub study 1 is to 1) uncover whether Sativex® has appetite stimulating properties defined as increased energy intake compared to placebo, 2) to develop a pharmacokinetic-pharmacodynamic model, and gain knowledge about the effect of Sativex® on other markers of appetite, the intraocular pressure of the eye and safety parameters. In sub study 1, subjects receive both Sativex® and placebo. Both Sativex® and placebo are administered as an oromucosal spray. Sativex consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dose of spray (Cannabis sativa L. extract, cannabis leaf and flower). Subjects receive three dose of spray two times during a trial day. Trial day 1 is planned \<14 days after inclusion and there is a 2-week break between trial days 1 and 2 due to a wash-out period. Follow-up visits/phonecalls are made on days 1, 2 and 7 after trial days 1 and 2. Sub study 2: Sub-study 2 is a single-dose pharmacokinetic study using gentamicin (Hexamycin®) as a renally excreted model drug. The purpose of sub study 2 is to compare the prediction accuracy of clearance estimates between eGFRpanel (creatinine-cystatinC-beta-2\_microglobulin-beta\_trace\_protein, eGFRcomb (creatinine-cystatinC), eGFRcreatinine (creatinine), uCrCl (24-hour urine creatinine clearance) and mGFR (measured GFR) as covariates in population based pharmacokinetic modeling of gentamicin. On trial day 3, gentamicin is used as the model substance for a drug that is excreted \> 90% renally. Gentamicin is administered as a single dose of 5 mg/kg as an intravenous injection (bolus). The marketed drug, Hexamycin® (40 mg / mL), is used for this purpose. Trial day 3 is held within 4 weeks after trial day 2. Follow-up visits are made on day 1 and 2 after trial day 3.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
17
Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
Clinical Research Centre
Hvidovre, Denmark
RECRUITINGDifference in energy intake (kJ) between Sativex® and placebo
Measured at test meal
Time frame: Trial days 1 and 2.
Differences in the objective function value of the population-based pharmacokinetic model when implementing renal clearance assessed by measured GFR (mL/min), or GFR estimates based on different endogenous markers, as covariates on gentamicin clearance
The objective function value (minus two times the log-likelihood) describes the prediction accuracy (goodness-of-fit) of a population pharmacokinetic model. A drop in the objective function value of 6.63 in a model with one (1) added covariate implemented on any specific parameter compared to a base model corresponds to a significant improvement in model fit with a p-value of 0.01 in a chi-squared test. Population-based pharmacokinetic modelling is an analysis method performed on pharmacokinetic data, i.e., plasma concentrations over time. Relevant pharmacokinetic parameters are estimated simultaneously by fitting the data to the model. The model structure is found through the analysis and determines which pharmacokinetic parameters are estimated. As a minimum, the clearance and distribution volume of the central compartment are estimated
Time frame: Trial day 3.
Differences in the objective function values of the population-based models of CBD and THC when implementing bodyweight, age, and body composition factors as covariates on the pharmacokinetic parameters of the model (e.g., clearance)
The objective function value (minus two times the log-likelihood) describes the prediction accuracy (goodness-of-fit) of a population pharmacokinetic model. A drop in the objective function value of 6.63 in a model with one (1) added covariate implemented on any specific parameter compared to a base model corresponds to a significant improvement in model fit with a p-value of 0.01 in a chi-squared test. Population-based pharmacokinetic-pharmacodynamic modelling is an analysis method performed on pharmacokinetic data, i.e. plasma concentrations over time, coupled to pharmacodynamic data. Relevant pharmacokinetic and -dynamic parameters are estimated simultaneously by fitting the data to the model. The model structure is found through the analysis and determines which pharmacokinetic and -dynamic parameters are estimated. As a minimum, the clearance and distribution volume of the central compartment are estimated
Time frame: Trial days 1 and 2.
Difference in subjective appetite between Sativex® and placebo
Using combined subjective appetite scores measured using 100-mm Visual Analogue Scales (VAS), with 0.0 as the minimum value and 10.0 as the maximum value. The following will be used to calculate a combined appetite score: \[desire to eat + hunger + prospective food consumption + (10.0 - fullness) + (10.0 - satiety)\], with higher scores indicating better appetite.
Time frame: Trial days 1 and 2.
Differences in the appetite hormones, total ghrelin and glucagon like peptide 1 (GLP-1) between Sativex® and placebo
The appetite hormones (total ghrelin, GLP-1) is measured from blood samples
Time frame: Trial days 1 and 2.
Change in the intraocular pressure of the eye between Sativex® and placebo
Measured by Icare ic100 tanometer
Time frame: Trial days 1 and 2.
Safety parameter (CNS effects) for Sativex®
Measured using 100-mm Visual Analogue Scales (VAS), with 0.0 as the minimum value and 10.0 as the maximum value. Higher scores indicate a larger effect.
Time frame: Trial days 1 and 2.
Safety parameter (cognition) for Sativex®
Measured using Hopkins Verbal Learning Test-Revised for a total score of the following sub-tests: 'Total recall', 'Delayed recall', 'Retention' and 'Recognition'. Higher scores indicate better performance.
Time frame: Trial days 1 and 2.
Safety parameter (balance disorders) for Sativex®
Bergs Balance Test is used to measure balance disorders. Balance disorders are defined as a summerated score of ≤45.
Time frame: Trial days 1 and 2.
Safety parameter (blood pressure) for Sativex®
Blood pressure is measured in millimeter of mercury (mmHg) using automatic standardized equipment.
Time frame: Trial days 1 and 2.
Safety parameter (heart rate) for Sativex®
Heart rate is measured in beats per minute (bpm) using automatic standardized equipment.
Time frame: Trial days 1 and 2.
Correlation coefficient between clearance of gentamicin and clearance determined as mGFR or eGFR
Pharmacokinetic modeling
Time frame: Trial day 3.
Change in plasma creatinine µmol/L between baseline and 22 hours after administration of gentamicin
Changes in kidney biomarkeres before and after administration of gentamicin
Time frame: Trial day 3
Change in plasma cystatin C mg/L between baseline and 22 hours after administration of gentamicin
Changes in kidney biomarkers before and after administration of gentamicin
Time frame: Trial day 3
Change in plasma NGAL ng/mL between baseline and 22 hours after administration of gentamicin
Changes in kidney biomarkers before and after administration of gentamicin
Time frame: Trial day 3
Change in plasma KIM-1 pg/mL between baseline and 22 hours after administration of gentamicin
Changes in kidney biomarkers before and after administration of gentamicin
Time frame: Trial day 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.